Therapeutic drug monitoring based on dasatinib dose optimization reduces PIEff incidence in CMLJuly 29, 2021CML
Low immune response to SARS-CoV-2 vaccines in patients with chronic myeloid neoplasmsJuly 29, 2021CML
CML: Daily nilotinib dosage in Italian clinical practice lower than the approved doseJune 24, 2021CML
ELTS vs. Sokal score may show better survival prediction in TKI-treated patients with CMLJune 24, 2021CML
CML-CP: Treatment failure higher in adolescents vs. children receiving frontline imatinibJune 24, 2021CML
CML: Single-dose of BNT162b2 vaccine induces neutralizing antibodies and polyfunctional T-cell responsesJune 24, 2021CML
Protein tyrosine phosphatase receptor gamma, a novel biomarker for TKI response in CMLJune 9, 2021CML
CIP2A is a potential biomarker for disease progression and treatment failure in CML-CPJune 9, 2021CML
CML-CP: Meeting TFR eligibility and receiving second-generation TKI frontline improves MRFSJune 9, 2021CML
